Being highly effective, the body-own molecules should henceforth advance the human wound healing process.

PLANTON succeeded for the first time in producing high-purely and biologically actively large quantities of recombinant AMPs in potato plants - at reduced energy use and improved product quality. With the production and development of these therapeutically active substances, PLANTON uses plants for the raw material manufacturing in medicine research.

A vegetable production system was established, where recombinant peptides are produced efficiently, advantageously and resource-saving in genetically modified potatoes. These peptides are also called Plant Made Pharmaceuticals (PMP).

PLANTON developed a technical purification procedure for recombinant AMPs from plants and facilitates the industrial use for this molecule class. At present, first molecules are in the pre-clinical development phase and were validated in a broadly aimed study regarding their effectiveness.

Currently it is intended to produce the AMPs not in genetically modified potatoes but in so named cell cultures. With a cell culture, plant cells are cultivated in a nutritional medium in the laboratory. The named advantages of the vegetable production system are preserved without the genetically modified plants being grown outdoors.

The procedure is not only more advantageous than others but can do without poisonous and carcinogenic chemicals, as they are required for the chemical synthesis of the active substances.